Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics
© 2023. The Author(s), under exclusive licence to European Society of Human Genetics..
The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate pharmacogenetics implementation in clinical practice by developing evidence-based guidelines to optimize pharmacotherapy. A guideline describing the gene-drug interaction between the genes CYP2D6, CYP3A4 and CYP1A2 and antipsychotics is presented here. The DPWG identified gene-drug interactions that require therapy adjustments when respective genotype is known for CYP2D6 with aripiprazole, brexpiprazole, haloperidol, pimozide, risperidone and zuclopenthixol, and for CYP3A4 with quetiapine. Evidence-based dose recommendations were obtained based on a systematic review of published literature. Reduction of the normal dose is recommended for aripiprazole, brexpiprazole, haloperidol, pimozide, risperidone and zuclopenthixol for CYP2D6-predicted PMs, and for pimozide and zuclopenthixol also for CYP2D6 IMs. For CYP2D6 UMs, a dose increase or an alternative drug is recommended for haloperidol and an alternative drug or titration of the dose for risperidone. In addition, in case of no or limited clinical effect, a dose increase is recommended for zuclopenthixol for CYP2D6 UMs. Even though evidence is limited, the DPWG recommends choosing an alternative drug to treat symptoms of depression or a dose reduction for other indications for quetiapine and CYP3A4 PMs. No therapy adjustments are recommended for the other CYP2D6 and CYP3A4 predicted phenotypes. In addition, no action is required for the gene-drug combinations CYP2D6 and clozapine, flupentixol, olanzapine or quetiapine and also not for CYP1A2 and clozapine or olanzapine. For identified gene-drug interactions requiring therapy adjustments, genotyping of CYP2D6 or CYP3A4 prior to treatment should not be considered for all patients, but on an individual patient basis only.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
European journal of human genetics : EJHG - 32(2024), 3 vom: 29. März, Seite 278-285 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Beunk, Lianne [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.03.2024 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41431-023-01347-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355071940 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355071940 | ||
| 003 | DE-627 | ||
| 005 | 20240313233400.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41431-023-01347-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM355071940 | ||
| 035 | |a (NLM)37002327 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Beunk, Lianne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.03.2024 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to European Society of Human Genetics. | ||
| 520 | |a The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate pharmacogenetics implementation in clinical practice by developing evidence-based guidelines to optimize pharmacotherapy. A guideline describing the gene-drug interaction between the genes CYP2D6, CYP3A4 and CYP1A2 and antipsychotics is presented here. The DPWG identified gene-drug interactions that require therapy adjustments when respective genotype is known for CYP2D6 with aripiprazole, brexpiprazole, haloperidol, pimozide, risperidone and zuclopenthixol, and for CYP3A4 with quetiapine. Evidence-based dose recommendations were obtained based on a systematic review of published literature. Reduction of the normal dose is recommended for aripiprazole, brexpiprazole, haloperidol, pimozide, risperidone and zuclopenthixol for CYP2D6-predicted PMs, and for pimozide and zuclopenthixol also for CYP2D6 IMs. For CYP2D6 UMs, a dose increase or an alternative drug is recommended for haloperidol and an alternative drug or titration of the dose for risperidone. In addition, in case of no or limited clinical effect, a dose increase is recommended for zuclopenthixol for CYP2D6 UMs. Even though evidence is limited, the DPWG recommends choosing an alternative drug to treat symptoms of depression or a dose reduction for other indications for quetiapine and CYP3A4 PMs. No therapy adjustments are recommended for the other CYP2D6 and CYP3A4 predicted phenotypes. In addition, no action is required for the gene-drug combinations CYP2D6 and clozapine, flupentixol, olanzapine or quetiapine and also not for CYP1A2 and clozapine or olanzapine. For identified gene-drug interactions requiring therapy adjustments, genotyping of CYP2D6 or CYP3A4 prior to treatment should not be considered for all patients, but on an individual patient basis only | ||
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a Aripiprazole |2 NLM | |
| 650 | 7 | |a 82VFR53I78 |2 NLM | |
| 650 | 7 | |a brexpiprazole |2 NLM | |
| 650 | 7 | |a 2J3YBM1K8C |2 NLM | |
| 650 | 7 | |a Clopenthixol |2 NLM | |
| 650 | 7 | |a 982-24-1 |2 NLM | |
| 650 | 7 | |a Clozapine |2 NLM | |
| 650 | 7 | |a J60AR2IKIC |2 NLM | |
| 650 | 7 | |a CYP1A2 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a CYP3A4 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.14.14.55 |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP1A2 |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP2D6 |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP3A |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Haloperidol |2 NLM | |
| 650 | 7 | |a J6292F8L3D |2 NLM | |
| 650 | 7 | |a Olanzapine |2 NLM | |
| 650 | 7 | |a N7U69T4SZR |2 NLM | |
| 650 | 7 | |a Pimozide |2 NLM | |
| 650 | 7 | |a 1HIZ4DL86F |2 NLM | |
| 650 | 7 | |a Quetiapine Fumarate |2 NLM | |
| 650 | 7 | |a 2S3PL1B6UJ |2 NLM | |
| 650 | 7 | |a Quinolones |2 NLM | |
| 650 | 7 | |a Risperidone |2 NLM | |
| 650 | 7 | |a L6UH7ZF8HC |2 NLM | |
| 650 | 7 | |a Thiophenes |2 NLM | |
| 700 | 1 | |a Nijenhuis, Marga |e verfasserin |4 aut | |
| 700 | 1 | |a Soree, Bianca |e verfasserin |4 aut | |
| 700 | 1 | |a de Boer-Veger, Nienke J |e verfasserin |4 aut | |
| 700 | 1 | |a Buunk, Anne-Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Guchelaar, Henk Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Houwink, Elisa J F |e verfasserin |4 aut | |
| 700 | 1 | |a Risselada, Arne |e verfasserin |4 aut | |
| 700 | 1 | |a Rongen, Gerard A P J M |e verfasserin |4 aut | |
| 700 | 1 | |a van Schaik, Ron H N |e verfasserin |4 aut | |
| 700 | 1 | |a Swen, Jesse J |e verfasserin |4 aut | |
| 700 | 1 | |a Touw, Daan |e verfasserin |4 aut | |
| 700 | 1 | |a van Westrhenen, Roos |e verfasserin |4 aut | |
| 700 | 1 | |a Deneer, Vera H M |e verfasserin |4 aut | |
| 700 | 1 | |a van der Weide, Jan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of human genetics : EJHG |d 1996 |g 32(2024), 3 vom: 29. März, Seite 278-285 |w (DE-627)NLM07496920X |x 1476-5438 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2024 |g number:3 |g day:29 |g month:03 |g pages:278-285 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41431-023-01347-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2024 |e 3 |b 29 |c 03 |h 278-285 | ||